Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01426113 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma
A Phase 3 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT01426113 is a Phase 3 study that was terminated before completion, run by Allergan. The registered enrollment target is 6 participants.
The verdict
NCT01426113, a Phase 3 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of a new formulation of bimatoprost ophthalmic solution compared to timolol ophthalmic solution in the treatment of paediatric patients with glaucoma.
Interventions
- DRUG bimatoprost vehicle
- DRUG bimatoprost ophthalmic solution formulation A
- DRUG timolol ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01426113
The ClinicalTrials.gov registry entry for NCT01426113 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which bimatoprost vehicle is the first listed.
NCT01426113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01426113 about?
NCT01426113 is a clinical study titled "A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma". The purpose of this study is to assess the safety and efficacy of a new formulation of bimatoprost ophthalmic solution compared to timolol ophthalmic solution in the treatment of paediatric patients with glaucoma.
What is the current status of trial NCT01426113?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2011-09. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01426113?
The interventions under investigation include: bimatoprost vehicle (DRUG), bimatoprost ophthalmic solution formulation A (DRUG), timolol ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT01426113?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.